| Index | — | P/E | — | EPS (ttm) | -8.86 | Insider Own | 3.00% | Shs Outstand | 214.34M | Perf Week | 2.32% |
| Market Cap | 40.33B | Forward P/E | — | EPS next Y | -5.79 | Insider Trans | -8.32% | Shs Float | 193.04M | Perf Month | -8.94% |
| Enterprise Value | 37.02B | PEG | — | EPS next Q | -2.35 | Short Float | 6.70% | Perf Quarter | -2.73% | ||
| Income | -1.77B | P/S | — | EPS this Y | — | Short Ratio | 6.61 | Perf Half Y | 27.23% | ||
| Sales | 0.00 | P/B | 15.48 | EPS next Y | — | ROA | -40.90% | Short Interest | 12.93M | Perf YTD | 136.25% |
| Book/sh | 12.16 | P/C | 10.24 | EPS next 5Y | — | ROE | -96.44% | 52W High | 224.31 -16.11% | Perf Year | 219.64% |
| Cash/sh | 18.37 | P/FCF | — | EPS past 3/5Y | — | ROIC | -40.82% | 52W Low | 56.66 232.10% | Perf 3Y | 845.10% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | — | Gross Margin | 0.00% | Volatility | 2.92% 4.68% | Perf 5Y | 603.44% |
| Dividend TTM | — | EV/Sales | — | EPS Y/Y TTM | — | Oper. Margin | 0.00% | ATR (14) | 7.96 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 11.38 | Sales Y/Y TTM | — | Profit Margin | 0.00% | RSI (14) | 45.87 | Recom | 2.04 |
| Dividend Gr. 3/5Y | — | Current Ratio | 11.38 | EPS Q/Q | -133.59% | SMA20 | -0.91% | Beta | 1.42 | Target Price | 253.47 |
| Payout | 0.00% | Debt/Eq | 0.24 | Sales Q/Q | — | SMA50 | -5.34% | Rel Volume | 0.67 | Prev Close | 191.31 |
| Employees | 883 | LT Debt/Eq | 0.24 | Earnings | Nov 04 | SMA200 | 20.34% | Avg Volume | 1.93M | Price | 188.17 |
| IPO Date | Feb 13, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -49.81% — | Net Debt/EBITDA | — | Volume | 1,286,122 | Change | -1.64% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-19-26 | Reiterated | Truist Securities | Buy | $240 → $241 |
| Oct-14-26 | Reiterated | RBC Capital | Outperform | $259 → $260 |
| Oct-08-26 | Reiterated | RBC Capital | Outperform | $251 → $259 |
| Oct-07-26 | Reiterated | Truist Securities | Buy | $231 → $240 |
| Sep-28-26 | Reiterated | Loop Capital Markets | $318 | |
| Sep-24-26 | Resumed | Goldman Sachs | Buy | $73 → $267 |
| Sep-10-26 | Reiterated | Morgan Stanley | Equal Weight | $255 |
| Sep-09-26 | Reiterated | Stifel Nicolaus | $215 → $230 | |
| Aug-31-26 | Reiterated | Needham | Buy | $235 → $275 |
| Aug-28-26 | Reiterated | UBS | Buy | $175 → $265 |
Revolution Medicines, Inc. is a precision oncology firm operating in the clinical development stage, dedicated to creating innovative treatments that target novel pathways crucial for RAS-driven cancers. Its pipeline includes several promising drug candidates: RMC-4630, an SHP2 inhibitor, is currently undergoing Phase 1/2 clinical trials for various solid tumors, such as gynecological and colorectal cancers. The company's portfolio also features RMC-5845, a selective inhibitor designed to target SOS1, a protein responsible for activating RAS within cells, and RMC-5552, a highly selective inhibitor for hyperactive mTORC1 signaling found in cancerous cells. Further expanding its therapeutic arsenal, Revolution Medicines is advancing RMC-6291, which selectively inhibits mutated forms of KRASG12C(ON) and NRASG12C(ON). Another promising compound, RMC-6236, specifically targets and inhibits a range of active RAS(ON) variants. Its research efforts also encompass other active RAS inhibitors aimed at KRASG13C(ON) and KRASG12D(ON) mutations. Revolution Medicines has established a collaborative partnership with Sanofi to research and develop SHP2 inhibitors, a collaboration that includes the development of RMC-4630. Established in 2014, Revolution Medicines, Inc. operates from its corporate headquarters situated in Redwood City, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 12 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 10 | 17 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | -10 | -17 | 0 | 12 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 328 | 187 | 97 | 76 | — | — | — | — | — | |
| Research and Development | 1,295 | 979 | 592 | 423 | — | — | — | — | — | |
| Other Operating Expense | -5 | 0 | 1 | 0 | — | — | — | — | — | |
| Operating Income | -1,627 | -1,182 | -690 | -487 | — | — | — | — | — | |
| Interest Expense | 59 | 24 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -81 | 75 | 89 | 48 | — | — | — | — | — | |
| Net Income Before Taxes | -1,768 | -1,131 | -601 | -440 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | -1 | -4 | — | — | — | — | — | |
| Consolidated Net Income | -1,768 | -1,131 | -600 | -436 | — | — | — | — | — | |
| Net Income From Continuing Operations | -1,768 | -1,131 | -600 | -436 | — | — | — | — | — | |
| Net Income | -1,768 | -1,131 | -600 | -436 | — | — | — | — | — | |
| EPS (Recurring) | -8.86 | -5.95 | -3.58 | -3.86 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -8.86 | -5.95 | -3.58 | -3.86 | — | — | — | — | — | |
| EPS (Diluted) | -8.86 | -5.95 | -3.58 | -3.86 | — | — | — | — | — | |
| EBITDA | -1,690 | -1,091 | -589 | -430 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | 270.07 | — | — | — | — | — | |
| Gross Margin | — | — | — | 100.00 | — | — | — | — | — | |
| Operating Margin | — | — | — | -4,058.33 | — | — | — | — | — | |
| Net Margin | — | — | — | -3,633.33 | — | — | — | — | — | |
| Shares Outstanding | 211 | 190 | 168 | 113 | — | — | — | — | — | |
| Market Capitalization | 39,704 | 15,134 | 7,348 | 3,241 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Mancini Anthony | Officer | Oct 26 '26 | Sale | 186.99 | 2,310 | 431,947 | 39,765 | Oct 28 |
| Mancini Anthony | Officer | Oct 26 '26 | Option Exercise | 33.62 | 2,310 | 77,662 | 42,075 | Oct 28 |
| Sandler Alan B. | Chief Development Officer | Sep 29 '26 | Option Exercise | 58.84 | 6,000 | 353,040 | 58,868 | Oct 01 |
| Sandler Alan B. | Chief Development Officer | Sep 29 '26 | Sale | 202.14 | 6,309 | 1,275,294 | 52,559 | Oct 01 |
| Cislini Jeff | SVP & General Counsel | Sep 25 '26 | Sale | 207.32 | 765 | 158,600 | 51,776 | Sep 29 |
| Mancini Anthony | Officer | Sep 25 '26 | Sale | 200.54 | 3,121 | 625,885 | 39,765 | Sep 28 |
| Mancini Anthony | Officer | Sep 25 '26 | Option Exercise | 33.62 | 3,121 | 104,928 | 42,886 | Sep 28 |
| Mancini Anthony | Officer | Sep 24 '26 | Sale | 200.00 | 587 | 117,400 | 39,765 | Sep 28 |
| ANDERSON ELIZABETH M | Director | Sep 22 '26 | Sale | 193.04 | 10,143 | 1,958,015 | 4,333 | Sep 24 |
| ANDERSON ELIZABETH M | Director | Sep 22 '26 | Option Exercise | 1.12 | 5,070 | 5,678 | 14,476 | Sep 24 |
| Mancini Anthony | Officer | Sep 18 '26 | Sale | 196.94 | 1,764 | 347,402 | 40,352 | Sep 22 |
| Mancini Anthony | Officer | Sep 16 '26 | Sale | 199.24 | 1,774 | 353,449 | 42,116 | Sep 18 |
| Sandler Alan B. | Chief Development Officer | Sep 16 '26 | Sale | 199.24 | 341 | 67,941 | 52,868 | Sep 18 |
| Anders Jack | Chief Financial Officer | Sep 16 '26 | Sale | 199.24 | 4,053 | 807,513 | 119,216 | Sep 18 |
| Cislini Jeff | SVP & General Counsel | Sep 16 '26 | Sale | 199.24 | 3,366 | 670,631 | 52,541 | Sep 18 |